Bylvay denied for missing prior authorization by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for bylvay are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Requires Prior Authorization for Bylvay

Blue Cross Blue Shield requires prior authorization (PA) for Bylvay (odevixibat) because it is a high-cost specialty medication for a rare hepatological condition. A PA requirement is not a denial of the drug itself — it is a gate that requires your prescriber to submit clinical documentation before BCBS will approve coverage. The most common reason a PA is "denied" at this stage is that the initial submission was incomplete, rather than that the patient truly fails the clinical criteria.

## Why It Is Appealable

If BCBS denies the prior authorization itself (rather than simply requesting more information), that decision is subject to the full appeal process:

• ACA §2719 / ERISA §503: You have the right to a full and fair internal appeal and then independent external review.
• External review window: Typically four months from the final adverse determination — confirm on your Explanation of Benefits.
• Expedited PA / Urgent review: If your condition requires the drug urgently, request expedited prior authorization or expedited external review; a decision is typically required within 72 hours.

## Appeal Process and Timeline

1. Request BCBS's current PA criteria for Bylvay in writing — this document lists exactly what clinical information is required. 2. Have your prescriber resubmit (or submit for the first time) a complete PA package addressing every criterion. 3. If the PA is formally denied, file an internal appeal within the deadline stated on the denial letter. 4. Escalate to external review if the internal appeal is denied.

## Documentation to Gather

• Diagnosis confirmation: Specialist chart notes, genetic testing results, and relevant laboratory findings confirming the specific cholestatic liver disease subtype.
• Disease severity documentation: Quantitative chart findings (lab trends, imaging, or biopsy) showing clinical burden and the need for pharmacological intervention.
• Prior treatment history: A dated list of all previously tried therapies, duration of each trial, and documented outcomes — failure, adverse event, or clinical intolerance.
• Prescriber medical-necessity letter: A letter addressing each PA criterion from BCBS's policy, citing the FDA-approved prescribing information and referencing the relevant specialty-society guideline organization (e.g., NASPGHAN, EASL).
• Current medication list: To address any step-therapy requirements or concomitant therapy questions.

## Criteria-Mapping Structure

Obtain BCBS's PA criteria document and Bylvay's FDA-approved prescribing information. For each requirement in the PA criteria, identify the corresponding chart finding and cite it specifically (date, source, result). This one-to-one mapping is the most effective format for a PA submission or appeal and reduces back-and-forth requests for additional information.